| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.097 | 0.007 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.43 | 0.007 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.008 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.008 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.008 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.009 |